CE Credits: 1.0 Hour(s)
Date Course Online: March 23, 2020
Last Revision Date: N/A
Course Expiration Date: June 30, 2020
Cost: Dentist, $50.00
Penn Dental Medicine Alumni, $37.50
Register: Click Here »
Liposomal bupivacaine (Exparel®) a recently approved sustained release formulation of bupivacaine has been touted to possess significant opioid-sparing effects. The first portion of this presentation will explore the pharmacokinetics of this unique delivery system and discuss its cost-effectiveness in the control of pain in dental outpatients. The second half of this presentation will present evidence-based data that supports or does not support some serious adverse drug interactions involving NSAID analgesic agents.
This course will enable participant to:
- Identify which class of psychotropic agents appears to enhance the bleeding potential of NSAID analgesic.
- Discuss why prescribing an NSAID to a patient on lithium might be “a bad idea”.
- Compare the FDA-approved indications of standard 0.5% bupivacaine plus 1:200,000 epinephrine with that of liposomal bupivacaine.
- Explain why a week of dosing with ibuprofen or naproxen could reduce the blood pressure lowering activity of some commonly prescribed anti-hypertensive agents.
- Discuss clinical research on the opioid-sparing effects of liposomal bupivacaine.
Elliot V. Hersh, DMD, MS, Phd, is currently a Professor of Pharmacology/Oral Surgery at the University of Pennsylvania School of Dental Medicine. He received his DMD degree from UMDNJ-NJDS in 1981 and his MS and PhD degrees from UMDNJ – Graduate School of Biomedical Sciences in 1983 and 1988 respectively. Since arriving at the Penn in 1988, Dr. Hersh has won the Dental School’s Excellence in the Teaching of Basic Science Award 20 different times and was also presented with a University Lindback Award in 1993, the highest teaching honor in the entire University. He has published more than 150 scientific articles, abstracts and book chapters in the areas of dental pharmacology, drug interactions, analgesics and local anesthetics. He is currently collaborating with faculty from the Penn Institute of Translational Medicine and Applied Therapeutics in identifying biomarkers that may predict individual analgesic response to NSAIDs. He remains passionate about providing students and practitioners with evidence-based data to reduce the unnecessary use of, and when needed the prescribing of excessive amounts of immediate-release opioid formulations. His scholarly and research contributions in the areas of local anesthesia and pain control were recognized by the International Association of Dental Research in 2007 when he was presented with the Distinguished Scientist Award in Pharmacology, Therapeutics and Toxicology.
Disclosure: Dr Hersh has received grant funding from Pfizer Consumer Healthcare the maker of Advil® products, the PENN Perleman School of Medicine Center of Precision Medicine and NIH/NIDA. He has also received consulting moneys from Bayer Pharmaceuticals, the maker of Aleve®.
Refund, Substitution and Cancellation Policy
Virtual attendance: No refunds will be issued.
University of Pennsylvania School of Dental Medicine is an ADA CERP Recognized Provider. ADA CERP is a service of the American Dental Association to assist dental professionals in identifying quality providers of continuing dental education. ADA CERP does not approve or endorse individual courses or instructors, nor does it imply acceptance of credit hours by boards of dentistry.
University of Pennsylvania School of Dental Medicine designates this activity for 1.0 continuing education credits.